Cargando…
COVID-19 vaccinations in Bhutan – Mix-and-Match to Boosters: An experience
Bhutan – a landlocked least developed country in the Himalayas – vaccinated 94% of its adults with the first dose of COVID-19 vaccine in March-April 2021, 90.2% with second dose in July 2021, and 89.1% with booster (third) dose by March 2022. The country used COVISHIELD (Oxford-Astrazeneca) vaccine...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023324/ https://www.ncbi.nlm.nih.gov/pubmed/35487809 http://dx.doi.org/10.1016/j.vaccine.2022.04.059 |
_version_ | 1784690319878520832 |
---|---|
author | Tamang, Saran Tenzin Dorji, Thinley |
author_facet | Tamang, Saran Tenzin Dorji, Thinley |
author_sort | Tamang, Saran Tenzin |
collection | PubMed |
description | Bhutan – a landlocked least developed country in the Himalayas – vaccinated 94% of its adults with the first dose of COVID-19 vaccine in March-April 2021, 90.2% with second dose in July 2021, and 89.1% with booster (third) dose by March 2022. The country used COVISHIELD (Oxford-Astrazeneca) vaccine for the first dose but decided to pursue a heterologous prime-boost strategy (“mix-and-match”) for the second dose using Moderna’s mRNA vaccine for adults. Bhutan rapidly rolled out Pfizer and Moderna vaccines for 12 to 17-year-olds through a school-based vaccination strategy followed by booster doses: 78.6% of adolescents aged 12–17 years were vaccinated with the first dose by August 2021, 92.8% with second dose by November 2021, and 79.7% with booster (third) dose by March 2022. More than 97% of children aged 5 to 11 years have received Pfizer’s Comirnaty vaccine for their first dose. Bhutan is steadily vaccinating its population and might soon become one of the few least developed countries to achieve herd immunity-level vaccination coverage with more than 80% of its population fully vaccinated. |
format | Online Article Text |
id | pubmed-9023324 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90233242022-04-22 COVID-19 vaccinations in Bhutan – Mix-and-Match to Boosters: An experience Tamang, Saran Tenzin Dorji, Thinley Vaccine Commentary Bhutan – a landlocked least developed country in the Himalayas – vaccinated 94% of its adults with the first dose of COVID-19 vaccine in March-April 2021, 90.2% with second dose in July 2021, and 89.1% with booster (third) dose by March 2022. The country used COVISHIELD (Oxford-Astrazeneca) vaccine for the first dose but decided to pursue a heterologous prime-boost strategy (“mix-and-match”) for the second dose using Moderna’s mRNA vaccine for adults. Bhutan rapidly rolled out Pfizer and Moderna vaccines for 12 to 17-year-olds through a school-based vaccination strategy followed by booster doses: 78.6% of adolescents aged 12–17 years were vaccinated with the first dose by August 2021, 92.8% with second dose by November 2021, and 79.7% with booster (third) dose by March 2022. More than 97% of children aged 5 to 11 years have received Pfizer’s Comirnaty vaccine for their first dose. Bhutan is steadily vaccinating its population and might soon become one of the few least developed countries to achieve herd immunity-level vaccination coverage with more than 80% of its population fully vaccinated. Elsevier Ltd. 2022-05-20 2022-04-22 /pmc/articles/PMC9023324/ /pubmed/35487809 http://dx.doi.org/10.1016/j.vaccine.2022.04.059 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Commentary Tamang, Saran Tenzin Dorji, Thinley COVID-19 vaccinations in Bhutan – Mix-and-Match to Boosters: An experience |
title | COVID-19 vaccinations in Bhutan – Mix-and-Match to Boosters: An experience |
title_full | COVID-19 vaccinations in Bhutan – Mix-and-Match to Boosters: An experience |
title_fullStr | COVID-19 vaccinations in Bhutan – Mix-and-Match to Boosters: An experience |
title_full_unstemmed | COVID-19 vaccinations in Bhutan – Mix-and-Match to Boosters: An experience |
title_short | COVID-19 vaccinations in Bhutan – Mix-and-Match to Boosters: An experience |
title_sort | covid-19 vaccinations in bhutan – mix-and-match to boosters: an experience |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023324/ https://www.ncbi.nlm.nih.gov/pubmed/35487809 http://dx.doi.org/10.1016/j.vaccine.2022.04.059 |
work_keys_str_mv | AT tamangsarantenzin covid19vaccinationsinbhutanmixandmatchtoboostersanexperience AT dorjithinley covid19vaccinationsinbhutanmixandmatchtoboostersanexperience |